Related content

Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins v 3 and v 5 in patients with advanced solid tumours

By Eskens F.A.L.M.   Dumez H.   Hoekstra R.   Perschl A.   Brindley C.   Bottcher S.   Wynendaele W.   Drevs J.   Verweij J.   van Oosterom A.T.  

European Journal of Cancer, Vol. 39, Iss. 7, 2003-05 ,pp. : 917-926

Elsevier

Access to resources Recommend Favorite

A clinical phase I and pharmacokinetic study of BBR 2778, a novel anthracenedione analogue, administered intravenously, 3 weekly

By Dawson L.K.   Jodrell D.I.   Bowman A.   Rye R.   Byrne B.   Bernareggi A.   Camboni G.   Smyth J.F.  

European Journal of Cancer, Vol. 36, Iss. 18, 2000-12 ,pp. : 2353-2359

Elsevier

Access to resources Recommend Favorite

Phase I study of a weekly schedule of a fixed dose of cisplatin and escalating doses of paclitaxel in patients with advanced oesophageal cancer

By Polee M.B.   Verweij J.   Siersema P.D.   Tilanus H.W.   Splinter T.A.W.   Stoter G.   Van der Gaast A.  

European Journal of Cancer, Vol. 38, Iss. 11, 2002-07 ,pp. : 1495-1500

Elsevier

Access to resources Recommend Favorite

Weekly administration of topotecan and paclitaxel in pretreated advanced cancer patients: a phase I/II study

By Stathopoulos George   Rigatos Sotiris   Christodoulou Christos   Malamos Nikos   Deliyiannis Filippos   Stathopoulos John   Skarlos Dimosthenis  

Cancer Chemotherapy and Pharmacology, Vol. 54, Iss. 3, 2004-09 ,pp. : 259-264

Springer Publishing Company

Access to resources Recommend Favorite

Phase I and pharmacokinetic study of paclitaxel and irinotecan for patients with advanced non-small cell lung cancer

By Kasai T.   Oka M.   Soda H.   Tsurutani J.   Fukuda M.   Nakamura Y.   Kawabata S.   Nakatomi K.   Nagashima S.   Takatani H.   Fukuda M.   Kinoshita A.   Kohno S.  

European Journal of Cancer, Vol. 38, Iss. 14, 2002-09 ,pp. : 1871-1878

Elsevier

Access to resources Recommend Favorite